Siu Christine 4
4 · Eidos Therapeutics, Inc. · Filed Nov 22, 2019
Insider Transaction Report
Form 4
Siu Christine
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2019-11-21$0.59/sh+25,000$14,750→ 61,470 total - Sale
Common Stock
2019-11-21$56.00/sh−200$11,200→ 36,470 total - Sale
Common Stock
2019-11-21$55.12/sh−24,800$1,366,877→ 36,670 total - Sale
Common Stock
2019-11-22$55.29/sh−601$33,232→ 36,470 total - Sale
Common Stock
2019-11-22$54.71/sh−9,399$514,224→ 37,071 total - Exercise/Conversion
Stock Option (right to buy)
2019-11-21−25,000→ 192,191 totalExercise: $0.59Exp: 2027-12-21→ Common Stock (25,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2019-11-21−10,000→ 182,191 totalExercise: $0.59Exp: 2027-12-21→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2019-11-22$0.59/sh+10,000$5,900→ 46,470 total
Footnotes (4)
- [F1]Represents the weighted average sale price of the shares sold from $55.00 to $55.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F2]Represents the weighted average sale price of the shares sold from $54.21 to $55.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Represents the weighted average sale price of the shares sold from $55.21 to $55.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F4]The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.